A Systematic Review on the Clinical Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Mellitus Patients

Published on:September 2018
Indian Journal of Pharmacy Practice, 2018; 11(3):141-147
Research Article | doi:10.5530/ijopp.11.3.31

A Systematic Review on the Clinical Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Mellitus Patients

Authors and affiliation (s):

Prudence A. Rodrigues*, Ndayishimye Samuel

Department of Pharmacy Practice, PSG College of Pharmacy, Peelamedu, Coimbatore 641004, Tamil Nadu, INDIA.


Context: clinical outcomes of Dipeptidyl Peptidase-4 inhibitors can be beneficial for the patients in controlling high blood sugar it can also cause potential adverse effects. Aim: The main objective of this study was to assess the risks and benefits of Dipeptidyl peptidase-4inhibitors (DPP-4I) in type 2 diabetes mellitus patients. Method: systematical articles on Dipeptidyl peptidase-4 inhibitors were reviewed from the year 2015 up to 2017 from 3 databases such as: EMBASE, COCHRANE and MEDSCAPE and some diabetes associations, the main such were: DPP-4 inhibitor, incretin, type 2 diabetes mellitus, Vildagliptin, Sitagliptin, Linagliptin, Saxagliptin, Alogliptin, 69 citations were included after screening for duplication and biased articles. Results: All DPP-4I are efficacious for improving blood glucose level among type 2 diabetes mellitus patients without causing hypoglycemic effects, and they can be used as monotherapy or in combination with other antidiabetic agents, Linagliptin offer uniqueness properties due to its non-renal excretion it improves microalbuminuria, whereas remaining DDP-4I cause a marginal changes on renal function, there is no hepatotoxicity among the DPP-4I no dose adjustment for Linagliptin, Sitagliptin, saxagliptin due non-hepatic excretion, only dose reduction is required for patients with minor hepatic functional impairment taking Vildagliptin and saxagliptin due to their partially elimination via liver,DPP-4I also protect patients for cardiovascular complications due its ability of reducing or maintaining the stability of body weight and lipid profile. They also show a low risk for increasing pancreatitis among T2DM and the others side effect were comparable less when compared to other anti-hyperglycemic agents. Conclusion: DPP-4I significantly control blood sugar level by decreasing glycated hemoglobin, fasting blood sugar, random blood sugar and they are not associated with hypoglycemic events they also minimize cardiovascular complications by reducing fats and weight in type 2 diabetes mellitus patients, in addition DPP-4I helps in renal and liver protection. Over all, DPP-4I reduce morbidity and mortality rate among T2DM patients.

Key words: DPP-4I, T2DM, Incretin, Saxagliptin, Linagliptin, Sitagliptin, Vildagliptin, Alogliptin.


The Official Journal of Association of Pharmaceutical Teachers of India (APTI)
(Registered under Registration of Societies Act XXI of 1860 No. 122 of 1966-1967, Lucknow)

Indian Journal of Pharmacy Practice (IJOPP) [ISSN-0974-8326] is the official journal of Association of Pharmaceutical Teachers of India (APTI) and is being published since 1967.


IJOPP uses reference linking service using Digital Object Identifiers (DOI) by Crossref. Articles from the year 2014 are being assigned DOIs for its permanent URLs